Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety and Efficacy of IBsolvMIR in Islet Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient on a waiting list for islet transplantation~2. Male and female patients age 18 to 60 years of age.~3. Ability to understand and provide written informed consent.~4. Mentally stable and able to comply with the procedures of the study protocol.~5. Clinical history compatible with type 1 diabetes with onset of disease at \< 40 years of age and insulin-dependence for \> 5 years at the time of enrolment.~6. Documented C-peptide \<0.1 nmol/L before first islet transplantation (stimulated in response to a MMTT or other confirmatory method).~7. All subjects must have received medical treatment of their diabetes under the guidance from an experienced endocrinologist. If not previously transplanted the patient must also have;~8. At least one episode of severe hypoglycemia in the past 1 year defined as an event with at least one of the following symptoms; memory loss, confusion, uncontrollable behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness, or visual symptoms, in which the subject was unable to treat him/herself and which was associated with either a blood/plasma glucose level \< 54 mg/dl \[3.0 mmol/L\] or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration OR~9. Reduced awareness of hypoglycemia as defined by a Clarke score of 4 or more.~Exclusion Criteria:~1. Patients with prior organ transplants other than a kidney graft and/or islets. A previous pancreas transplant can be accepted if it failed within the first week due to thrombosis and the graft was removed.~2. Patients with body mass index (BMI) \> 30.~3. Insulin requirement \> 0.7 Unit/kg/day at screening.~4. Consistently abnormal liver function tests (\> 1.5 x ULN on two consecutive measurements \> 2 weeks apart) at screening.~5. Proliferative untreated diabetic retinopathy~6. Increased risk for thrombosis (ex. homozygous APC-resistance) or bleeding (INR\>1.5)~7. Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin~8. Patients with increased cardiac risk defined as;~   * unstable coronary artery disease requiring hospitalization or revascularization within 6 months prior to baseline visit~  * chronic heart failure which required hospitalization 30 days prior to baseline visit~9. Patients with active infections, unless treatment is not judged necessary by the investigators~10. Patients with serological evidence of infection with HIV, hepatitis B (patients with serology consistent with previous vaccination and a history of vaccination are acceptable) or hepatitis C.~11. Patients with active peptic ulcer disease, symptomatic gallstones or portal hypertension.~12. Patients who are pregnant or breastfeeding, or who intend to become pregnant.~13. Patients of childbearing potential not willing to use adequate double contraception with \< 1% failure rate after the screening visit until the last visit.~14. Active alcohol or substance abuse~15. Patients with evidence of high-level sensitization (PRA\> 50% with flow cytometry).~16. Patients with psychological conditions that make it unsafe to undergo islet transplantation or which preclude compliance with prescribed therapy~17. HbA1c \> IFCC 100 mmol/mol, at screening.~18. Patients with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with IBsolvMIR.~19. Patients participating in or having participated in any other clinical drug studies in the past four weeks.~20. History of bleeding disorders~21. History of severe hypersensitivity~22. Previous known heparin-induced thrombocytopenia (HIT)~23. Patients with severe hepatic or renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- IBsolvMIR (Type: EXPERIMENTAL): Study drug IBsolvMIR administered intravenously at 18 mg/kg on day of transplantation and 3 mg/kg on post-operative days 1, 3, 6.
- Heparin (Type: ACTIVE_COMPARATOR): Heparin treatment according to clinical praxis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues